Evommune, Inc.
NYSE:EVMN · New York Stock Exchange
-$0.17 today
Vol 0.48M · Avg 0.38M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NYSE:EVMN · Revenue to Net Income
Key Ratios
Analysis
$10.0M of revenue converted into -$76.0M of net income for the selected period. Gross margin is 25.0% and net margin is -31.2%, showing how much revenue survives after costs and taxes. EPS is $-2.39, tying the income statement back to per-share earnings.
Income Statement
Annual data · 3 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | $13.0M +85.7% | $7.0M +40.0% | $5.0M | $888.0M | $1.0B | $809.6M |
| Cost of Revenue | $0 -100.0% | $1.3M +28.7% | $1.0M | -$1.7B | $344.8M | $725.6M |
| Gross Profit | $13.0M +127.6% | $5.7M +42.8% | $4.0M | $11.6B | $10.3B | $8.9B |
| Gross Margin | 100.0% +18.4pp | 81.6% +1.6pp | 80.0% | 26.4% | 45.5% | 9.8% |
| Research & Development | $74.0M +15.3% | $64.2M +100.8% | $32.0M | $1.2B | $378.4M | $983.2M |
| Selling, General & Admin | $20.0M +74.4% | $11.5M +16.5% | $9.9M | $811.0M | $1.4B | $620.6M |
| Operating Expenses | $94.1M +24.2% | $75.7M +80.9% | $41.9M | -$15.9B | $3.6B | $5.3B |
| Depreciation & Amortization | $1.4M +7.9% | $1.3M +28.7% | $1.0M | $419.0M | $1.2B | $374.2M |
| EBITDA | -$67.5M -3.0% | -$65.5M -98.5% | -$33.0M | $10.0B | $12.6B | -$15.2B |
| EBITDA Margin | -519.1% +416.4pp | -935.5% -275.6pp | -659.9% | 14.3% | 10.0% | 5.6% |
| Operating Income | -$81.1M -15.8% | -$70.0M -85.0% | -$37.9M | $9.0B | $10.6B | $12.3B |
| Operating Margin | -623.6% +376.6pp | -1000.2% -243.2pp | -757.0% | 11.2% | 18.7% | 16.6% |
| Interest Income | $3.3M +2.5% | $3.2M -15.9% | $3.9M | $875.4M | $1.3B | -$1.5B |
| Interest Expense | $0 -100.0% | $34.0K -41.4% | $58.0K | $801.2M | $969.2M | $1.1B |
| Other Income / Expenses | $12.2M +280.7% | $3.2M -15.6% | $3.8M | $368.6M | -$1.6B | -$1.5B |
| Income Before Tax | -$68.9M -3.1% | -$66.8M -96.2% | -$34.1M | $13.9B | -$15.6B | $3.3B |
| Pre-Tax Margin | -529.8% +424.6pp | -954.4% -273.3pp | -681.1% | 15.4% | 13.3% | 20.8% |
| Income Tax Expense | $0 | $0 | $0 | $375.6M | $666.8M | $1.3B |
| Net Income | -$68.9M -3.1% | -$66.8M -96.2% | -$34.1M | $5.1B | $5.0B | $4.9B |
| Net Margin | -529.8% +424.6pp | -954.4% -273.3pp | -681.1% | 47.3% | 7.4% | 12.4% |
| EPS (Basic) | -$2 +4.0% | -$2 -100.9% | -$1 | $591.2M | $1.2B | $400.8M |
| EPS (Diluted) | -$2 +4.0% | -$2 -100.9% | -$1 | $777.4M | $620.6M | $766.2M |
| Weighted Avg Shares | $31.5M +4.8% | $30.1M +0.0% | $30.1M | $724.2M | $892.2M | $757.8M |
| Weighted Avg Shares (Diluted) | $31.5M +4.8% | $30.1M +0.0% | $30.1M | $566.0M | $319.6M | $1.2B |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND
$5.46B
Galapagos N.V.
GLPG
$1.84B
Zymeworks Inc.
NASDAQ:ZYME
$1.69B
Fortrea Holdings Inc.
NASDAQ:FTRE
$1.44B
EyePoint Pharmaceuticals, Inc.
NASDAQ:EYPT
$1.12B
Climb Bio, Inc.
NASDAQ:CLYM
$779.01M
OmniAb, Inc.
NASDAQ:OABI
$262.00M
Artiva Biotherapeutics, Inc.
NASDAQ:ARTV
$238.63M
Codexis, Inc.
NASDAQ:CDXS
$225.88M
Karyopharm Therapeutics Inc.
NASDAQ:KPTI
$209.63M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does EVMN generate?
Evommune, Inc. (EVMN) reported $13.00M of revenue in fiscal 2025.
Is EVMN profitable?
Evommune, Inc. (EVMN) reported -$68,870,000.00 of net income, with a net margin of -529.8%.
Explore More
Continue the stock analysis
Jump to another research area for this company.